Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium

Cardiovascular Research

Volumn 89, Issue 2, 2011, Pages 410-418

  Kaza, Elisabeth ^a   Ablasser, Klemens ^a   Poutias, Dimitrios ^a   Griffiths, Eric R ^a   Saad, Fawzy A ^a   Hofstaetter, Jochen G ^a   Del Nido, Pedro J ^a   Friehs, Ingeborg ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Angiogenesis inhibitor; Hypertrophy; Placental growth factor

Indexed keywords

MESSENGER RNA; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HEART MUSCLE PERFUSION; HEART VENTRICLE HYPERTROPHY; IMMUNOBLOTTING; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGING; ANIMALS; ANIMALS, NEWBORN; AORTA; BLOTTING, WESTERN; CAPILLARIES; CARDIOMEGALY; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; LIGATION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PREGNANCY PROTEINS; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 78751550090     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq321     Document Type: Article

References (42)

1. Friehs I, Moran AM, Stamm C, Choi YH, Cowan DB, McGowan FX et al. Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury. Ann Thorac Surg 2004;77:2004-2010.
2. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 2002;21:1939-1947.
3. Flanagan MF, Aoyagi TM, Arnold LW, Maute C, Fujii AM, Currier J et al. Effects of chronic heparin administration on coronary vascular adaptation to hypertension and ventricular hypertrophy in sheep. Circulation 1999;100:981-987.
4. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794-814. (Pubitemid 29411709)
5. Ferrara N, Gerber HG, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
6. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;225: 989-991.
7. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-26995.
8. Meyer RD, Mohammadi M, Rahimi N. A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1. J Biol Chem 2006; 281:867-875.
9. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39:469-478.
10. Shinkaruk S, Bayle M, Lain G, Deleris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 2003;3:95-117.
11. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90: 10705-10709.
12. Seko Y, Takahashi N, Shibuya M, Yazaki Y. Pulsatile stretch stimulates vascular endothelial growth factor (VEGF) secretion by cultured rat cardiac myocytes. Biochem Biophys Res Commun 1999;254:462-465.
13. Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 2005;57:1R-7R.
14. Maynard SE, Min JY, Merchan J, Merchan J, Lim KH, Li J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658.
15. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226:324-328.
16. Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443:993-997.
17. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269:25646-25654.
18. Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor (PlGF), which is related to vascular endothelial growth factor (VEGF). Cell Growth Differ 1996;7:213-221.
19. Friehs I, Moran AM, Stamm C, Colan SD, Takeuchi K, Cao-Danh H et al. Impaired glucose transporter activity in pressure-overload hypertrophy is an early indicator of progression to failure. Circulation 1999;100(Suppl. II):II187-II193.
20. Moran AM, Friehs I, Takeuchi K, Stamm C, Hammer PE, McGowan FX et al. Noninvasive serial evaluation of myocardial mechanics in pressure overload hypertrophy of rabbit myocardium. Herz 2003;28:52-62.
21. Friehs I, Cao-Danh H, Nathan M, McGowan FX, del Nido PJ. Impaired insulin-signaling in hypertrophied hearts contributes to ischemic injury. Biochem Biophys Res Com 2005; 331:15-22.
22. Friehs I, Barillas R, Vasilyev NV, Roy N, McGowan FX, del Nido PJ. Vascular endothelial growth factor (VEGF) prevents apoptosis and preserves contractile function in hypertrophied infant heart. Circulation 2006;114(Suppl. I):I290-I295.
23. Friehs I, Margossian RE, Moran AM, Cao-Danh H, Moses MA, del Nido PJ. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res Cardiol 2006;101:204-213.
24. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis following hindlimb ischemia type 2 diabetes mellitus. Differential regulation of vascular endothelial growth factor receptor 1 and soluble VEGFR-1. Circ Res 2007;101:1-10.
25. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
26. Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992;313:355-364.
27. Rakusan K, Flanagan MF, Geva T, Southern J, VanPraagh R. Morphometry of human coronary capillaries during normal growth and the effect of age in left ventricular pressure-overload hypertrophy. Circulation 1992;86:38-46.
28. Hudlicka O, Brown MD, Egginton S. Angiogenesis in skeletal and cardiac muscle. Physiol Rev 1992;72:369-417.
29. Laughlin MH, McAllister RM. Exercise training-induced coronary vascular adaptation. J Appl Physiol 1992;73:2209-2225.
30. Breisch EA, White FC, Nimmo LE, Bloor CM. Cardiac vasculature and flow during pressure-overload hypertrophy. Am J Physiol 1986;251:H1031-H1037.
31. Tomanek RJ, Palmer PJ, Peiffer GL, Schreiber KL, Eastham CL, Marcus ML. Morphometry of canine coronary arteries, arterioles, and capillaries during hypertension and left ventricular hypertrophy. Circ Res 1986;58:38-46.
32. Flanagan MF, Aoyagi T, Currier JJ, Colan SD, Fuji AM. Effect of young age on coronary adaptations to left ventricular pressure overload hypertrophy in sheep. J Am Coll Cardiol 1994;24:1786-1796.
33. Engelmann GL, Vitullo JC, Gerrity RG. Morphometric analysis of cardiac hypertrophy during development, maturation, and senescence in spontaneously hypertensive rats. Circ Res 1987;60:487-494.
34. Anversa P, Ricci R, Olivetti G. Coronary capillaries during normal and pathological growth. Can J Cardiol 1986;2:104-113.
35. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70.
36. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990;5:519-524.
37. Iyer S, Leonidas DD, Swaminathan GJ, Maglione D, Battisti M, Tucci M et al. The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution. J Biol Chem 2001;276:12153-12161.
38. Marti HH. Vascular endothelial growth factor. Adv Exp Med Biol 2002;513:375-394.
39. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, Demol M et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-583.
40. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-943.
41. Disalvo J, Bayne ML, Conn G, Kwok PW, Trivedi PG, Soderman DD et al. Purification and characterization of a naturally occurring vascular endothelial growth factor placenta growth factor heterodimer. J Biol Chem 1995;270:7717-7123.
42. Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA et al. Heterodimers of placenta growth factor/vascular endothelial growth factor: endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 1996;271:3154-3162.